Evidence map›Paper›PMID 39740869›Full record

ArticleIn vivo (Athens, Greece)

Proactive Symptom Monitoring by Pharmacists Using a Cancer Patient Support App in Out-patient Oral Multi-kinase Inhibitor Therapy: Feasibility Study of a Small Patient Population.

Maki Todo, Suguru Shirotake, G O Kaneko, Kojun Okamoto, Masashi Sugasawa, Mitsuhiko Nakahira, Shiho Ishikawa, Noriko Wakui, Yoshinori Makino, Toshiaki Saeki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maki TodoDepartments of Pharmacy, Saitama Medical University, Saitama International Medical Center, Saitama, Japan m_todo@saitama-med.ac.jp.
Suguru ShirotakeDepartments of Uro-Oncology, Saitama Medical University, Saitama International Medical Center, Saitama, Japan.
G O KanekoDepartments of Uro-Oncology, Saitama Medical University, Saitama International Medical Center, Saitama, Japan.
Kojun OkamotoDepartments of Gastroenterological Surgery, Saitama Medical University, Saitama International Medical Center, Saitama, Japan.
Masashi SugasawaDepartments of Head and Neck Oncology, and Saitama Medical University, Saitama International Medical Center, Saitama, Japan.
Mitsuhiko NakahiraDepartments of Head and Neck Oncology, and Saitama Medical University, Saitama International Medical Center, Saitama, Japan.
Shiho IshikawaDepartments of Pharmacy, Saitama Medical University, Saitama International Medical Center, Saitama, Japan.
Noriko WakuiDepartments of Breast Oncology, Saitama Medical University, Saitama International Medical Center, Saitama, Japan.
Yoshinori MakinoDepartments of Pharmacy, Saitama Medical University, Saitama International Medical Center, Saitama, Japan.
Toshiaki SaekiDepartments of Breast Oncology, Saitama Medical University, Saitama International Medical Center, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimMeasures to control adverse events (AEs) in the use of oral multi-kinase inhibitors (OMI) are important for the continuation of treatment. PATIENTS AND

methodsIn this study, oncology pharmacists monitored symptoms of patients receiving outpatient therapy with OMIs in real-time using a smartphone Web app for the early detection/early treatment of AEs. This feasibility study evaluated the effects of using the app in 10 patients compared with data from 10 patients who did not use the app.

resultsIn the app group, grade 3 AEs were reported in all patients on the day of their occurrence. In contrast, in the no-app group, it took 1-22 days for pharmacists to detect these AEs, among whom 2 patients needed emergency consultations and admissions due to grade 3 AEs. In the app group, 1 patient had an emergency consultation, without admission. The percentage of patients requiring 10 minutes or more for symptom checking during the interview before the physician's examination was significantly lower (p=0.001), and the frequency of telephone calls was also significantly lower (p=0.029) in the app group compared to the no app group.

conclusionUsing the Web app facilitates the early detection of AEs, contributing to reducing the need for emergency consultations and admissions, and minimizing the time pharmacists spend confirming symptoms with patients.

Indexed as

Feasibility StudiesMobile ApplicationsNeoplasmsPharmacistsProtein Kinase InhibitorsAdministration, OralAdultAgedFemaleHumansMaleMiddle AgedOutpatientsProtein Kinase Inhibitorscancer patientsmonitoringoncology pharmacistOral multi-kinase inhibitoroutpatientsWeb app

Identifiers

PMID39740869
PMCPMC11705115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.